Sociodemographic and clinical biomarkers, liver injury indices (Fibrosis-4 [FIB-4], LiverRisk, NAFLD fibrosis score [NFS]), liver enzymes and inflammatory markers (GGT, AST, ALT, CRP), liver function tests (albumin, bilirubin, PT-INR), psychiatric and substance use comorbidities as well as current smoking were assessed in the four groups using analysis of covariance (ANCOVA). This evidence concerns the gene GPT and fibrosis.